New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects

Huang, Maohua; Lin, Yunning; Wang, Chenran; Deng, Lijuan; Chen, Minfeng; Assaraf, Yehuda G.; Chen, Zhe‐Sheng; Ye, Wen‐Cai; Zhang, Dongmei

doi:10.1016/j.drup.2022.100849

Cited by 74 publications

(47 citation statements)

References 312 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AATs resistance can be intrinsic if present at the beginning of the treatment or acquired if it occurs after a transient therapy benefit, followed by relapse, i.e., a restart of tumor growth and progression [ 68 ]. Various cells, molecules, and biological processes play a role in AATs resistance: pro-angiogenic factors release, tumor cells extravasation and intravasation, metastatization, recruitment of tumor-associated microenvironment cells, and angiogenic or non-angiogenic methods of tumor growth [ 69 ].…”

Section: Discussionmentioning

confidence: 99%

Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors

et al. 2022

View full text Add to dashboard Cite

Background: Vascular co-option is one of the main features of brain tumor progression. It is identified using histopathological analysis, but no antibody-specific markers were found, and no universally accepted histological features were defined. Methods: We employed double immunohistochemical stainings for CD31, P-gp, S100A10, and mitochondria on formalin-fixed, paraffin-embedded human samples of IDH-WT glioblastoma, IDH-mutant astrocytoma, and meningioma to study vascular co-option across different brain tumors and across normal, peritumoral, and intratumoral areas using the Aperio colocalization algorithm, which is a valid and robust method to handle and investigate large data sets. Results: The results have shown that (i) co-opted vessels could be recognized by the presence of metabolically overactive (evaluated as mitochondria expression) and P-gp+ or S100A10+ tumor cells surrounding CD31+ endothelial cells; (ii) vascular co-option occurs in the intratumoral area of meningioma and astrocytoma; and (iii) vascular co-option is prevalent in peritumoral glioblastoma area. Conclusions: The described approach identifies new markers for cellular components of the vessel wall and techniques that uncover the order and localization of vascularization mechanisms, which may contribute to developing new and possibly more effective therapeutic strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In 2004, the FDA authorized bevacizumab as the first antiangiogenic medication for use in the first-line treatment of metastatic colorectal cancer ( 152 ). It is a recombinant human IgG-1 monoclonal antibody against VEGF that prevents VEGF from binding to VEGFR by binding to VEGF, and inhibition of endothelial proliferation and activation leads to antiangiogenic and antitumour effects.…”

Section: Therapies Targeting Inflammation In Drmentioning

confidence: 99%

The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications

et al. 2022

View full text Add to dashboard Cite

Diabetic retinopathy is one of the most common complications of diabetes mellitus and the leading cause of low vision and blindness worldwide. Mounting evidence demonstrates that inflammation is a key mechanism driving diabetes-associated retinal disturbance, yet the pathophysiological process and molecular mechanisms of inflammation underlying diabetic retinopathy are not fully understood. Cytokines, chemokines, and adhesion molecules interact with each other to form a complex molecular network that propagates the inflammatory and pathological cascade of diabetic retinopathy. Therefore, it is important to understand and elucidate inflammation-related mechanisms behind diabetic retinopathy progression. Here, we review the current understanding of the pathology and pathogenesis of inflammation in diabetic retinopathy. In addition, we also summarize the relevant clinical trials to further suggest inflammation-targeted therapeutics for prevention and management of diabetic retinopathy.

show abstract

“…Currently, the main target of anti-angiogenic therapy is the vascular endothelial growth factor (VEGF) pathway. Some patients do benefit from anti-VEGF/VEGFR therapy, especially in renal cell carcinoma (RCC), colorectal cancer (CRC), and glioblastoma multiforme [9] , [10] . However, a large number of patients do not respond or develop resistance after treatment [9] , [11] .…”

Section: Introductionmentioning

confidence: 99%

“…Some patients do benefit from anti-VEGF/VEGFR therapy, especially in renal cell carcinoma (RCC), colorectal cancer (CRC), and glioblastoma multiforme [9] , [10] . However, a large number of patients do not respond or develop resistance after treatment [9] , [11] . This could be caused by the reason that tumor tissues can produce alternative angiogenic growth factors to stimulate angiogenesis and ensure blood flow [12] .…”

Section: Introductionmentioning

confidence: 99%

Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues

Zhang

Lü

et al. 2023

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects

Cited by 74 publications

References 312 publications

Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors

Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors

The role of inflammation in immune system of diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications

Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues

Contact Info

Product

Resources

About